バイオ医薬品CMOの世界市場レポート 2025年

バイオ医薬品CMOの市場規模は、今後数年で急成長が見込まれます。2029年には480億4,000万米ドルに成長し、CAGRは14.4％に達します。予測期間の成長は、遠隔医療や遠隔治験の増加、世界の健康への取り組み、可処分所得の増加、世界の健康への取り組みに起因すると考えられます。予測期間の主な動向には、先進医療の優位性、デジタル化とインダストリー4.0、継続的製造、持続可能性とグリーンプラクティスなどがあります。

ライフサイエンス分野へのベンチャーキャピタル投資の増加は、バイオ医薬品受託製造機関（CMO）市場の成長を促進すると予想されます。ライフサイエンス分野には、生物に関する研究開発に携わる企業や組織が含まれます。ベンチャーキャピタル投資の強さは、パラメータや仮定が変更されたときに、モデル、テスト、システムがどれだけ効果的に動作できるかを示しています。例えば、2024年5月、英国の政府機関である保健社会福祉省は、中核的なバイオ医薬品セクターの2021/22年の売上高は467億ポンド（593億2,000万米ドル）で、ライフサイエンス産業全体の43％を占めると報告しました。さらに2024年、オーストラリアを拠点とする団体AusBiotechは、バイオテクノロジー分野の総収益は2021年までに56億6,000万米ドル（86億7,000万豪ドル）に達し、成長率は4.4%に達すると述べました。この多額の投資によりバイオ医薬品の製造が促進され、バイオ医薬品CMO市場の成長に寄与すると予想されます。

慢性疾患の負担増は、バイオ医薬品CMO市場の成長を促進する見通しです。慢性疾患は、継続的な医学的管理を必要とする長引く健康状態を特徴とし、世界の健康上の大きな課題となっています。バイオ医薬品CMOは、医薬品開発の迅速化、費用対効果の高い生産の確保、高品質基準の維持により、慢性疾患への対応に重要な役割を果たしています。国立医学図書館によると、米国の50歳以上の人口は2020年の1億3,725万人から2050年には2億2,113万人へと61.11％増加し、少なくとも1つの慢性疾患を抱える人の数は2020年の7,152万2,000人から2050年には1億4,266万人へと99.5％増加すると予測されています。このような慢性疾患の負担増は、バイオ医薬品CMO市場の主要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のバイオ医薬品CMO市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のバイオ医薬品CMO市場の成長率分析
• 世界のバイオ医薬品CMO市場の実績：規模と成長、2019～2024年
• 世界のバイオ医薬品CMO市場の予測：規模と成長、2024～2029年、2034年
• 世界のバイオ医薬品CMO総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオ医薬品CMO市場：製品別、実績と予測、2019～2024年、2024～2029年、2034年
• 生物製剤
• バイオシミラー
• 世界のバイオ医薬品CMO市場：供給源別、実績と予測、2019～2024年、2024～2029年、2034年
• 哺乳類
• 非哺乳類
• 世界のバイオ医薬品CMO市場：サービス別、実績と予測、2019～2024年、2024～2029年、2034年
• 製造
• 充填および仕上げ作業
• 分析および品質管理調査
• 包装
• 世界のバイオ医薬品CMO市場：生物製剤のサブセグメンテーション：製品別、実績と予測、2019～2024年、2024～2029年、2034年
• モノクローナル抗体
• 組換えタンパク質
• ワクチン
• 細胞・遺伝子治療
• 世界のバイオ医薬品CMO市場：バイオシミラーのサブセグメンテーション：製品別、実績と予測、2019～2024年、2024～2029年、2034年
• バイオシミラーモノクローナル抗体
• バイオシミラー組換えタンパク質
• バイオシミラーインスリン
• バイオシミラー成長ホルモン

第7章 地域別・国別分析

• 世界のバイオ医薬品CMO市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のバイオ医薬品CMO市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオ医薬品CMO市場：競合情勢
• バイオ医薬品CMO市場：企業プロファイル
  • Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • Fujifilm Diosynth Biotechnologies USA Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Samsung Biologics Overview, Products and Services, Strategy and Financial Analysis
  • WuXi AppTec Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Catalent, Inc.
• Rentschler Biopharma SE
• Boehringer Ingelheim
• Recipharm AB
• AGC Biologics
• CMC Biologics
• KBI Biopharma
• Vetter Pharma International GmbH
• Emergent BioSolutions Inc.
• Aenova Group
• Synlogic, Inc.
• MedImmune（AstraZeneca）
• BioLife Sciences
• Bio-Xcellence（Boehringer Ingelheim）
• AbbVie Contract Manufacturing

第32章 世界市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 市場の最近の動向

第35章 市場の潜在力が高い国、セグメント、戦略

• バイオ医薬品CMO市場2029年-最も新しい機会を提供する国
• バイオ医薬品CMO市場2029年-最も新しい機会を提供するセグメント
• バイオ医薬品CMO市場2029年-成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Biopharmaceutical CMO (Contract Manufacturing Organization) is a business that provides manufacturing services, capable of producing small quantities for preclinical research and development, as well as larger quantities required for clinical trials and commercialization. Biopharmaceutical CMOs play a crucial role in reducing overall operational risk and time to market for pharmaceutical products.

The main types of biopharmaceutical CMO products include biologics and biosimilars. Biologics encompass a diverse range of products derived from human, animal, or microbial sources, serving as medications. These substances are produced from living organisms or contain components thereof. Examples of biologic medications include vaccines, blood products, cells, allergens, genes, tissues, and recombinant proteins. Biopharmaceutical CMO products can be sourced from various origins, including mammalian and non-mammalian sources. Biopharmaceutical CMO services cover a spectrum of activities such as manufacturing, fill and finish operations, analytical and quality control studies, and packaging. These services are crucial for pharmaceutical companies looking to outsource certain aspects of their production processes, allowing them to focus on research, development, and commercialization efforts.

The biopharmaceutical CMO market research report is one of a series of new reports from The Business Research Company that provides biopharmaceutical CMO market statistics, including biopharmaceutical CMO industry global market size, regional shares, competitors with a biopharmaceutical CMO market share, detailed biopharmaceutical CMO market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical CMO industry. This biopharmaceutical CMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biopharmaceutical CMO market size has grown rapidly in recent years. It will grow from $24.81 billion in 2024 to $28.09 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increasing demand for biopharmaceuticals, globalization, rise in healthcare expenditure, regulatory support, increased research funding.

The biopharmaceutical CMO market size is expected to see rapid growth in the next few years. It will grow to $48.04 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rise in telehealth and remote trials, global health initiatives, rise in disposable income, global health initiatives. Major trends in the forecast period include advanced therapies dominance, digitalization and industry 4.0, continuous manufacturing, sustainability and green practices.

An increase in the strength of venture capital investments in the life science sector is expected to fuel the growth of the biopharmaceutical Contract Manufacturing Organization (CMO) market. The life sciences sector includes businesses and organizations involved in research and development related to living organisms. The strength of venture capital investments indicates how effectively a model, test, or system can operate when parameters or assumptions are changed. For example, in May 2024, the Department of Health and Social Care, a UK-based government agency, reported that the core biopharmaceutical sector generated £46.7 billion ($59.32 billion) in revenue in 2021/22, representing 43% of the entire life sciences industry. Additionally, in 2024, AusBiotech, an organization based in Australia, stated that the biotechnology sector reached USD 5.66 billion (AU$8.67 billion) in total revenues by 2021, with a growth rate of 4.4%. This significant investment is anticipated to boost the manufacturing of biopharmaceuticals, contributing to the growth of the biopharmaceutical CMO market.

The increasing burden of chronic diseases is poised to fuel the growth of the biopharmaceutical CMO market. Chronic diseases, characterized by prolonged health conditions requiring ongoing medical management, represent a significant global health challenge. Biopharmaceutical CMOs play a crucial role in addressing chronic diseases by expediting drug development, ensuring cost-effective production, and maintaining high-quality standards. According to the National Library of Medicine, the US population aged 50 and older is projected to increase by 61.11% from 137.25 million in 2020 to 221.13 million in 2050, with the number of individuals with at least one chronic disease estimated to rise by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. This growing burden of chronic diseases is a key driver for the biopharmaceutical CMO market.

Technological advancement emerges as a prominent trend in the biopharmaceutical CMO market. Major companies in this sector are focusing on advancing technologies through research and development, leveraging the Internet of Things (IoT). The IoT involves the application of networked sensors and actuators for monitoring and controlling manufacturing environments. The vast amount of data generated by IoT-enabled systems can be analyzed to enhance production efficiency, automate tasks, and enable adaptable manufacturing. In February 2022, M2Cloud and Thales collaborated to develop an IoT-based LTE monitoring system for biopharmaceutical monitoring. This system facilitates real-time monitoring of freezers, refrigerated warehouses, and delivery boxes, ensuring temperature and position information verification. Technological advancements like these contribute to the safety and efficiency of biopharmaceutical product management, driving growth in the biopharmaceutical CMO market.

Leading companies in the biopharmaceutical CMO market are increasingly pursuing strategic partnerships to create innovative biopharmaceutical products. These collaborations enable biopharmaceutical CMO firms to pool resources and expertise, enhance research and development capabilities, broaden their market presence, and speed up commercialization. This approach ultimately fosters innovation and growth within the biopharmaceutical CMO sector. For example, in May 2024, BioConnection, a contract manufacturing company based in the Netherlands, joined forces with AGC Biologics, a contract development and manufacturing organization in the United States. Through this partnership, they aim to provide a streamlined, all-encompassing solution for biopharmaceutical development and manufacturing, thereby expediting timelines and simplifying processes for drug developers.

In May 2023, WACKER, a chemical company based in Germany, acquired ADL BioPharma for an undisclosed amount. This acquisition aims to strengthen WACKER's biotechnology operations and expand its fermentation capacities for sustainably produced food ingredients, aligning with its future growth goals. ADL BioPharma is a contract manufacturing company located in Spain that specializes in the development and production of high-quality fermentation products.

Major companies operating in the biopharmaceutical cmo market include Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Synlogic, Inc., MedImmune (AstraZeneca), BioLife Sciences, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, AltheaDx, Daxor Corporation, Genomatica, Inc., Astellas Pharma, Juno Therapeutics (Celgene), Medpace, Celerion, Evonik Industries AG

North America was the largest region in the biopharmaceutical CMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical CMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the biopharmaceutical CMO market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The biopharmaceutical CMO market includes revenues earned by entities by process development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biopharmaceutical CMO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biopharmaceutical cmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biopharmaceutical cmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biopharmaceutical cmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Biologics; Biosimilars
• 2) By Source: Mammalian; Non-Mammalian
• 3) By Service: Manufacturing; Fill And Finish Operations; Analytical And QC Studies; Packaging
• Subsegments:
• 1) By Biologics: Monoclonal Antibodies; Recombinant Proteins; Vaccines; Cell and Gene Therapies
• 2) By Biosimilars: Biosimilar Monoclonal Antibodies; Biosimilar Recombinant Proteins; Biosimilar Insulins; Biosimilar Growth Hormones
• Companies Mentioned: Lonza Group AG; Fujifilm Diosynth Biotechnologies USA Inc.; Thermo Fisher Scientific Inc.; Samsung Biologics; WuXi AppTec
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biopharmaceutical CMO Market Characteristics

3. Biopharmaceutical CMO Market Trends And Strategies

4. Biopharmaceutical CMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Biopharmaceutical CMO Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biopharmaceutical CMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biopharmaceutical CMO Market Growth Rate Analysis
• 5.4. Global Biopharmaceutical CMO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biopharmaceutical CMO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biopharmaceutical CMO Total Addressable Market (TAM)

6. Biopharmaceutical CMO Market Segmentation

• 6.1. Global Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• Biosimilars
• 6.2. Global Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammalian
• Non-Mammalian
• 6.3. Global Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Manufacturing
• Fill And Finish Operations
• Analytical And QC Studies
• Packaging
• 6.4. Global Biopharmaceutical CMO Market, Sub-Segmentation Of Biologics, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Cell and Gene Therapies
• 6.5. Global Biopharmaceutical CMO Market, Sub-Segmentation Of Biosimilars, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biosimilar Monoclonal Antibodies
• Biosimilar Recombinant Proteins
• Biosimilar Insulins
• Biosimilar Growth Hormones

7. Biopharmaceutical CMO Market Regional And Country Analysis

• 7.1. Global Biopharmaceutical CMO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biopharmaceutical CMO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biopharmaceutical CMO Market

• 8.1. Asia-Pacific Biopharmaceutical CMO Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biopharmaceutical CMO Market

• 9.1. China Biopharmaceutical CMO Market Overview
• 9.2. China Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biopharmaceutical CMO Market

• 10.1. India Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biopharmaceutical CMO Market

• 11.1. Japan Biopharmaceutical CMO Market Overview
• 11.2. Japan Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biopharmaceutical CMO Market

• 12.1. Australia Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biopharmaceutical CMO Market

• 13.1. Indonesia Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biopharmaceutical CMO Market

• 14.1. South Korea Biopharmaceutical CMO Market Overview
• 14.2. South Korea Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biopharmaceutical CMO Market

• 15.1. Western Europe Biopharmaceutical CMO Market Overview
• 15.2. Western Europe Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biopharmaceutical CMO Market

• 16.1. UK Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biopharmaceutical CMO Market

• 17.1. Germany Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biopharmaceutical CMO Market

• 18.1. France Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biopharmaceutical CMO Market

• 19.1. Italy Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biopharmaceutical CMO Market

• 20.1. Spain Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biopharmaceutical CMO Market

• 21.1. Eastern Europe Biopharmaceutical CMO Market Overview
• 21.2. Eastern Europe Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biopharmaceutical CMO Market

• 22.1. Russia Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biopharmaceutical CMO Market

• 23.1. North America Biopharmaceutical CMO Market Overview
• 23.2. North America Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biopharmaceutical CMO Market

• 24.1. USA Biopharmaceutical CMO Market Overview
• 24.2. USA Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biopharmaceutical CMO Market

• 25.1. Canada Biopharmaceutical CMO Market Overview
• 25.2. Canada Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biopharmaceutical CMO Market

• 26.1. South America Biopharmaceutical CMO Market Overview
• 26.2. South America Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biopharmaceutical CMO Market

• 27.1. Brazil Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biopharmaceutical CMO Market

• 28.1. Middle East Biopharmaceutical CMO Market Overview
• 28.2. Middle East Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biopharmaceutical CMO Market

• 29.1. Africa Biopharmaceutical CMO Market Overview
• 29.2. Africa Biopharmaceutical CMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biopharmaceutical CMO Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biopharmaceutical CMO Market, Segmentation By Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biopharmaceutical CMO Market Competitive Landscape And Company Profiles

• 30.1. Biopharmaceutical CMO Market Competitive Landscape
• 30.2. Biopharmaceutical CMO Market Company Profiles
  • 30.2.1. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Fujifilm Diosynth Biotechnologies USA Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Samsung Biologics Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. WuXi AppTec Overview, Products and Services, Strategy and Financial Analysis

31. Biopharmaceutical CMO Market Other Major And Innovative Companies

• 31.1. Catalent, Inc.
• 31.2. Rentschler Biopharma SE
• 31.3. Boehringer Ingelheim
• 31.4. Recipharm AB
• 31.5. AGC Biologics
• 31.6. CMC Biologics
• 31.7. KBI Biopharma
• 31.8. Vetter Pharma International GmbH
• 31.9. Emergent BioSolutions Inc.
• 31.10. Aenova Group
• 31.11. Synlogic, Inc.
• 31.12. MedImmune (AstraZeneca)
• 31.13. BioLife Sciences
• 31.14. Bio-Xcellence (Boehringer Ingelheim)
• 31.15. AbbVie Contract Manufacturing

32. Global Biopharmaceutical CMO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biopharmaceutical CMO Market

34. Recent Developments In The Biopharmaceutical CMO Market

35. Biopharmaceutical CMO Market High Potential Countries, Segments and Strategies

• 35.1 Biopharmaceutical CMO Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biopharmaceutical CMO Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biopharmaceutical CMO Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer